Press Releases

As the end of this year draws near, we at The Lynx Group would like to take this opportunity to thank all of you for an amazing 2020. We also share a celebration of our victories and accomplishments with everyone, while reflecting on ways to improve as we progress into the new year! The success of The Lynx Group is based on the effective and vibrant relationships we have forged over the years; we simply wouldn’t be where we are without you. We are extremely grateful for the opportunity to work with, and for you! Read More ›

The Lynx Group, a global strategic alliance of medical communications and education companies, is pleased to announce that its Journal of Hematology Oncology Pharmacy™ (JHOP) has been named the official publication of the Hematology/Oncology Pharmacy Association (HOPA). Read More ›

The Academy of Oncology Nurse & Patient Navigators^® (AONN+) is proud to announce that it has been granted membership in the American College of Surgeon’s Commission on Cancer. Read More ›

The Academy of Oncology Nurse & Patient Navigators® (AONN+) is proud to announce that it has been granted membership in the American College of Surgeon’s Commission on Cancer (CoC). Read More ›

Onco360, the largest independent provider of Oncology Pharmacy Services in the U.S., announced today that Bill Gittinger has joined the organization as a National Director for its Managed Care business. Read More ›

New York – February 12, 2014 – Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, is proud to be part of the limited Specialty Pharmacy Network of IMBRUVICA™ (ibrutinib). Read More ›

New York – February 12, 2014 – Onco360, the nation’s fastest-growing independent Oncology Pharmacy and Clinical Support Services company, is proud to be part of the limited Specialty Pharmacy Network of IMBRUVICA™ (ibrutinib). Read More ›

The FDA recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage). Read More ›

The FDA recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage). Read More ›

Onco360 Expected to Rapidly Grow Revenues Over the Next Several Years Read More ›